GlassScriptPhysician profile
Laura H Taber
NPI 1538756952
$1,159.15
in general payments reported to CMS, 2019-2025
18 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $435 · 2024: $435 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $175.59 | 2023 | |
| Sage Therapeutics, LLC | $151.14 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $143.03 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $117.80 | 2024 | |
| Abbvie INC. | $77.83 | 2023-2024 | |
| Exact Sciences Corporation | $67.30 | 2024 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $64.26 | 2023-2025 | |
| Hologic Sales and Service, LLC | $56.70 | 2023-2025 | Aptima, Affirm Prone Biopsy System, Thinprep 2000 Processor |
| Coopersurgical, INC. | $54.92 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $50.72 | 2023-2025 | Phexxi, Solosec, Phexx |
| Supernus Pharmaceuticals, INC. | $46.98 | 2025 | Qelbree |
| Organon LLC | $40.49 | 2023 | Nexplanon |
| Millicent US INC | $36.43 | 2024-2025 | Femring, Intrarosa |
| Duchesnay USA Incorporated | $20.04 | 2023 | Osphena, Bonjesta |
| Merck Sharp & Dohme LLC | $19.08 | 2024 | Gardasil, Gardasil 9 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $15.03 | 2025 | Arista |
| Exeltis, USA INC. | $13.44 | 2024 | Slynd |
| Aspira Women'S Health INC | $8.37 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Taber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.